These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21642688)

  • 1. Balancing access and evaluation in the approval of new cancer drugs.
    Miller FG; Joffe S
    JAMA; 2011 Jun; 305(22):2345-6. PubMed ID: 21642688
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 3. Investigational drugs and the constitution.
    Dresser R
    Hastings Cent Rep; 2006; 36(6):9-10. PubMed ID: 17278864
    [No Abstract]   [Full Text] [Related]  

  • 4. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 5. "Right to Try" Laws: The Gap between Experts and Advocates.
    Dresser R
    Hastings Cent Rep; 2015; 45(3):9-10. PubMed ID: 25944200
    [No Abstract]   [Full Text] [Related]  

  • 6. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 7. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 8. Should terminally ill patients have access to phase I drugs?
    Bristol N
    Lancet; 2007 Mar; 369(9564):815-6. PubMed ID: 17366691
    [No Abstract]   [Full Text] [Related]  

  • 9. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remarks by the Commissioner of Food and Drugs.
    Kessler DA
    Food Drug Law J; 1996; 51(2):207-15. PubMed ID: 11817358
    [No Abstract]   [Full Text] [Related]  

  • 11. Demand grows for early access to promising cancer drugs.
    Baldwin J
    J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318
    [No Abstract]   [Full Text] [Related]  

  • 12. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 13. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ; Woodcock J
    JAMA; 2011 Dec; 306(23):2608-9. PubMed ID: 22187281
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient group seeks overhaul of FDA clinical trial system in court.
    Hede K
    J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seamless Oncology-Drug Development.
    Prowell TM; Theoret MR; Pazdur R
    N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
    [No Abstract]   [Full Text] [Related]  

  • 17. Abbreviated approval process in the works for 'biosimilar' drugs.
    Sipkoff M
    Manag Care; 2007 Apr; 16(4):52, 55. PubMed ID: 17491291
    [No Abstract]   [Full Text] [Related]  

  • 18. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 19. The seamless approach to drug development in oncology.
    Pazdur R
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA appointee faces angry, demoralized staff.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.